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ABSTRACT
Objectives: Few in vitro studies have examined the participation of resistin, a recently
discovered adipokine, in oxidative processes. We investigated whether in vivo treatment with
the antioxidant vitamin C might affect resistin serum levels.
Design: Randomized prospective open trial.
Setting: San Giovanni Battista Hospital, Turin, Italy.
Participants: Eighty healthy individuals.
Intervention: Administration of 2 g of ascorbic acid orally for 2 wk (n ¼ 40; experimental
group) or no supplementation (n ¼ 40; control group).
Outcome measures: The primary end point was the between-group difference in the
before–after change in resistin serum level after vitamin C supplementation. Secondary
endpoints were the within- and between-group changes in glucose, insulin, lipid parameters,
C-reactive protein fasting values, and markers of oxidative stress.
Results: In the experimental group, vitamin C supplementation was significantly associated
with both resistin concentration reduction (from 4.3 6 1.5 to 2.9 6 0.8 ng/ml; 95% confidence
interval [CI]  1.87,  1.03) and ascorbic acid level increase (from 9.4 6 2.9 to 19.0 6 5.2 mg/l;
95% CI 7.9, 11.2). In the control group, resistin levels did not change significantly (from 4.2 6
1.0 to 4.3 6 0.9 ng/ml; 95% CI  0.07, 0.37). The between-group differences were highly
significant (p , 0.001). Vitamin C supplementation was also associated with a statistically
significant reduction in nitrotyrosine level and incremental increase in reduced glutathione. In a
linear regression model, within-individual changes in vitamin C concentrations were inversely
correlated with changes in resistin levels in both groups (each unit increase of vitamin C
corresponded to a decrease of about 0.10 units of resistin levels (95% CI 0.13, 0.08; p , 0.001).
Conclusion: This is to our knowledge the first randomized trial in humans that has
demonstrated that short-term vitamin C supplementation could significantly reduce resistin
levels, independent of changes in inflammatory or metabolic variables. Future investigations of
resistin participation in oxidative processes are warranted.
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PLoS CLINICAL TRIALSINTRODUCTION
Resistin, a recently described adipokine belonging to the
cysteine-rich secretory protein family, was originally de-
scribed as an adipocyte-derived polypeptide that links obesity
and insulin resistance in mice [1]. However, in humans,
resistin is expressed at very low concentrations in adipose
cells [2], but at high levels in mononuclear leukocytes,
macrophages, spleen cells, and bone marrow cells [3]. Striking
differences in the genomic organization and cellular source
of resistin in rodents versus humans make the biological
effects found in the mouse not readily transferable to humans
[4–6]. Accordingly, an increasing number of reports have
raised doubts regarding the possibility of an important
relationship between human resistin and various metabolic
disturbances characteristic of obesity and type 2 diabetes [7–
13].
Resistin was originally found to be related to proteins
induced during lung inﬂammation [14], and the likelihood
that it may be involved in the inﬂammation process [4,12,15–
22] is suggested by the high expression levels of resistin in
leukocytes, the associations between this protein and inﬂam-
matory markers, and the resistin’s ability to stimulate in vivo
inﬂammatory cytokines.
Data supporting resistin participation in oxidative pro-
cesses have been sporadically published. Signiﬁcant inter-
action between a single nucleotide polymorphism in the
promoter of the human resistin gene and a marker of
oxidative stress (NAD(P)H:quinone oxidoreductase I) has
been found [23]. Retinoic acid, the acid form of vitamin A,
inhibited the expression of resistin in mice and reduced the
higher resistin levels of ten men affected by psoriasis [24,25].
Resistin serum levels were inversely associated with nitro-
tyrosine (NT), a product of free radical activity [22]; resistin
inhibited endothelial nitric oxide synthase activation in vitro,
thus reducing nitric oxide (NO) bio-availability [26].
The aim of this explicative trial was to evaluate whether an
in vivo short-term treatment with an antioxidant vitamin
(vitamin C) might substantially affect resistin serum levels.
For this purpose, serum resistin values were evaluated in a
group of healthy participants, randomized to receive orally 2
g of ascorbic acid daily for 2 wk. Values of fasting glucose,
insulin, total and high-density lipoprotein (HDL) cholesterol,
triglycerides, and C-reactive protein (CRP) and markers of
oxidative stress were measured.
METHODS
Participants
After obtaining approval from the San Giovanni Battista
Hospital Ethical Committee and informed written consent
from participants, a randomized prospective open trial was
carried out. Healthy European-descent volunteers aged 20–50
y were recruited from the staff of the San Giovanni Battista
Hospital in Turin. Exclusion criteria were as follows: current
pregnancy; hyperglycemia (fasting glucose . 6.1 mmol/l);
hypertension (blood pressure   140/90 mm Hg); impaired
renal function (serum creatinin   106 lmol/l); known
cardiovascular disease, liver disease, or any other systemic
conditions; use of any drug (estrogen included); and being on
a particular diet and/or vitamin or other nutrient supple-
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Editorial Commentary
Background: Resistin is a hormone that is produced by fat cells. Much
of the work on resistin has been done in mice, and as a result of this
research the hormone was thought to explain the link between obesity
and development of diabetes. In obese mice, higher levels of resistin
are seen, and this hormone seems to interfere with the normal role of
insulin in reducing blood sugar levels. However, the exact biochemical
pathways in mice and humans seem to be very different, and it is not
obvious whether resistin plays the same role in the development of
diabetes in humans as it does in mice. At the same time, some
researchers have suggested links between resistin and oxidative stress,
which is thought to be involved in the development of certain diseases,
particularly cardiovascular disease. The researchers here wanted to
more fully explore these links by finding out whether an antioxidant,
vitamin C, affected levels of resistin in blood. The researchers carried
out a trial in healthy human participants, who were randomized to
receive 2 g of vitamin C daily for two weeks, or no treatment. The
primary outcome of the trial was the change in resistin levels in blood,
and the researchers also looked at the levels of other biochemical
variables in blood, such as fasting glucose, insulin, cholesterol, fatty
acids, and nitrotyrosine.
What the trial shows: The researchers recruited 80 participants into the
trial, and 40 were randomized to receive 2 g of vitamin C supplemen-
tation for two weeks. Forty individuals acted as ‘‘controls’’ and received
no intervention over the two weeks of the trial. Outcomes were assessed
for all but two individuals in the control group. Overall, levels of resistin
in blood fell substantially over the course of the trial among the
individuals in the vitamin C supplementation group, but not in the
control arm of the trial, and this difference between groups was
statistically significant. The levels of many other biochemical markers in
blood, such as glucose, cholesterol, fatty acids, and insulin, did not show
statistically significant changes between the randomized groups.
However, levels of two markers of oxidative stress did change: levels of
nitrotyrosine, which is associated with cell damage and inflammation,
seemed to drop in the vitamin C group relative to the control group, and
levels of reduced glutathione (an antioxidant) seemed to increase in the
vitamin C group relative to the control group.
Strengths and limitations: In this trial, all individuals were randomized
at once to the two study groups. While this is unconventional (normally,
participants are randomized one by one, as they are screened and
deemed eligible for a study), the process would be likely to prevent bias
in allocation of individuals to the study groups. Although participants
were not blinded to which study group they were assigned to, the
laboratory staff measuring biochemical marker levels in blood were
blinded to the study groups. A key limitation of this study is that the
participants in the control arm did not receive placebo tablets, but rather
received no treatment. A placebo control group would have enabled the
researchers to blind participants as to whether they received vitamin C or
no active intervention. Participants’ knowledge of their group assign-
ment (e.g., to receive vitamin C or no intervention) may have affected
their response in the trial. Finally, the trial was conducted on a small
group of healthy individuals, and no clinical outcomes were examined.
Therefore, although the findings are intriguing, their clinical meaning is
not clear.
Contribution to the evidence: There are few other studies that have
been carried out in humans examining the possibility of a link between
resistin levels and oxidative stress. This study suggests that vitamin C
administration reduces blood levels of resistin in humans. This finding
does not yet clearly point to a specific role for resistin in disease
processes or human disease, but raises questions for further study.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.ments. All procedures conformed to the principles of the
Declaration of Helsinki.
Outcomes
The primary end point was the between-group difference in
the before–after change in resistin serum levels after 2 wk of
vitamin C treatment in the experimental group. Secondary
end points were the within- and between-group comparisons
of changes in the other inﬂammatory and oxidative variables
measured.
Sample Size
On the basis of our previous data [22], a sample of at least 34
individuals per group was required to detect a standardized
difference of 0.5 standard deviations in resistin levels
between groups, with a statistical power of 80% and a two-
tailed 0.05 a-value. Taking into account the limitations of
these assumptions and the possibility of missing some
individuals, the total sample size was increased to 40
individuals per group.
Recruitment
In June–July 2005, a total of 80 eligible participants were
enrolled and submitted in the morning, at fasting, to
measurements of weight, waist circumference, and blood
pressure, and to determinations of serum glucose, total
cholesterol, HDL cholesterol, triglyceride, insulin, high-
sensitivity CRP (hs-CRP), vitamin A, vitamin C, vitamin E,
oxidized and reduced glutathione, NT, and resistin levels.
None of the participants showed impaired values of blood
pressure, glucose, or cholesterol. Data were collected on
smoking habits and physical activity via an interview, and on
mean daily nutrient intake via a 3-d food record.
Interventions in the two arms were either daily 2 g of
ascorbic acid supplementation or no supplementation for 14
d. Tablets of 1 g of ascorbic acid were consumed twice a day,
one at fasting upon awakening and the second 12 h later,
every day for 14 consecutive days. All the participants were
advised to continue their habitual diet and perform their
usual physical activity.
The second blood sample, likewise after 8–12 h of fasting,
was collected from the two groups in September–November
2005. The date of the second assessment was ﬁxed in
advanced for all participants, well before treatment began
for the experimental group, so that any inﬂuence of the
condition of the participant or his eating patterns on the date
of assessment can be ruled out.
In the experimental group a blood sample was collected the
morning after the last vitamin C tablet had been taken.
During the time lag between the ﬁrst (June–July 2005) and the
second assessment (September–November 2005) no change in
health status occurred; participants maintained their weight,
waist circumference, and blood pressure values. None of the
participants started any treatment (including anti-inﬂamma-
tory drugs) or were affected by any pathological conditions,
including acute or chronic inﬂammatory conditions or
infections.
Randomization: Sequence Generation
Participants were stratiﬁed according to age, sex, smoking
habits, body mass index, and fasting levels of glucose, hs-CRP,
vitamin C, and resistin. After collection of all baseline data
for all participants, the randomization procedure was
automatically performed by a statistician, using a SAS
program developed to minimize the differences between
the two groups for all the stratifying variables. The ﬁnal
distribution was 40 participants on vitamin C supplementa-
tion (experimental group) and 40 not supplemented (control
group).
Randomization: Allocation Concealment
When the results of baseline tests were available for all 80
participants, random allocation with a minimization algo-
rithm was centrally performed in a single step. The
researchers received then two lists of nominative data (40
for the experimental group and 40 for the control group). In
this way the possibility for researchers to predict or inﬂuence
the allocation of participants was completely prevented.
Measurements
The 3-d food record consisted of a detailed written food diary
kept prospectively: the participants were instructed to record
everything they ate or drank during two consecutive week
days and one weekend day.
Weight and waist and hip circumference were measured
using standard protocols. Systolic and diastolic blood
pressures were measured twice with a standard mercury
sphygmomanometer in a sitting position, after at least 10 min
of rest. Values reported are the mean of the two determi-
nations.
Physical activity during leisure time was deﬁned as light
(inactive, ,4 h/wk), moderate (4 h/wk), or heavy (.4 h/wk)
[27].
Serum glucose was measured by the glucose oxidase
method, and triglycerides and HDL cholesterol by enzymatic
colorimetric assay (Hitachi 911 Analyzer, Sentinel, Milan,
Italy). Serum insulin values were determined by immunor-
adiometric assay (Radim, Pomezia, Italy; intra-assay coefﬁ-
cient of variation (CV) 1.9%, inter-assay CV 6.2%). Serum
CRP levels were measured by a high-sensitivity latex
agglutination method (hs-CRP) on the Hitachi 911 Analyzer
(intra-assay and inter-assay CVs respectively 0.95% and
1.3%). Serum NT values were determined by an ELISA kit
(HyCult Biotechnology Pantec, Turin, Italy; inter-assay
precision 3.3%; intra-assay CV 5%). Serum resistin values
were analyzed by ELISA (BioVendor, Brno, Czech Republic);
the intra-assay and inter-assay CVs were, respectively, 2.8%
and 5.5%.
Plasma vitamin C levels were detected by HPLC (Solvent
Delivery System 9012, with a UV-Visible Detector 9050,
Varian, Walnut Creek, California, United States); intra-assay
and inter-assay CVs respectively 4.8% and 5.9%). Plasma
vitamin A and vitamin E were simultaneously evaluated by
HPLC (Chromsystems Instruments, Munich, Germany; intra-
assay and inter-assay CVs respectively 3.3% and 5.6%). Total
and reduced glutathione in red blood cells were analyzed by
HPLC after a derivatization of hemolyzed samples with
ammonium 7-ﬂuorobenzo-2-oxa-1,3-diazole-4-sulphonate,
using a ﬂuorescence detector (Varian 9070) with excitation
at 385 nm and emission at 515 nm. Oxidized glutathione was
calculated as the difference between total and reduced
glutathione (intra-assay and inter-assay CVs respectively
4.1% and 5.3%).
All blood samples underwent laboratory testing in blind.
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We applied the Student’s t-test for paired data to investigate
before–after changes in the concentrations of several blood
variables within the experimental and control groups. To
assess whether these before–after changes were different
between the two groups, t-tests for independent samples,
assuming either equal or unequal variances, were performed.
In order to compare the between-group differences of
variables with different units of measurement, all the
comparisons were done using the corresponding stand-
ardized values (mean/overall standard deviation).
Since the distributions of hs-CRP, insulin, and triglyceride
values were positively skewed, their levels were log-trans-
formed, in order to approximate a normal distribution. In all
the statistical analyses the log-transformed values of these
variables were used, but for descriptive purposes, median
(and interquartile range) of untransformed values are
reported.
To explore the biological relationship between resistin and
vitamin C, we ﬁtted a linear regression model, using before–
after change of resistin as the response variable and change of
ascorbic acid level and group (experimental or control) as
predictors. To reduce the inﬂuence of outliers, a robust linear
regression technique, using Huber and Tukey bi-weights, was
chosen [28,29]. Since neither the group variable nor the
interaction between group and vitamin C change were
statistically signiﬁcant when the effect of vitamin C change
was accounted for, only the latter was retained in the model
as an explicatory variable.
All the statistical analyses were performed with STATA (v.
8.0; StataCorp, College Station, Texas, United States).
RESULTS
Participant Flow
Out of the 40 participants in the control group, two were lost
during follow-up (they moved away). No participant discon-
tinued treatment or was lost during follow-up in the
experimental group. Data from 78 participants were thus
analyzed. The ﬂow diagram of the trial is reported in Figure 1.
Baseline Data
Basal clinical and laboratory characteristics of all the enrolled
participants by group are shown in Table 1. No meaningful
difference was evident between the two groups. Habitual
nutrient intake patterns were very similar between the two
groups; in particular, estimated vitamin C intake from food
was 142.5 6 77.2 and 144.8 6 70.4 mg/d, respectively, in the
experimental and control groups. Similarly, intake of total
calories; total fat; polyunsaturated, saturated, and monounsa-
turated fat (as energy percent); ﬁber; and vitamin A and E
were not signiﬁcantly different between the two groups (data
not shown).
Outcomes and Estimation
After vitamin C supplementation, ascorbic acid plasma levels
signiﬁcantly increased in the experimental group, while a
slight reduction was observed in the control group (Table 2).
Resistin serum concentrations showed a signiﬁcant reduction
in the experimental group (from 4.3 to 2.9 ng/ml) and a small,
not signiﬁcant, increase in the control group (from 4.2 to 4.3
ng/ml). The differences between groups in the blood levels of
vitamin C and resistin after supplementation were highly
signiﬁcant (p , 0.001) (Table 2). Reduced glutathione
concentrations increased in both groups, but the increment
was more than 2-fold higher in the experimental group.
Levels of NT signiﬁcantly decreased in the experimental
group, and slightly increased in the controls, giving a
between-group difference of borderline statistical signiﬁ-
cance. Values of hs-CRP slightly increased in the controls, and
no signiﬁcant change was evident for fasting glucose, insulin,
lipid variables, or other antioxidant vitamins within or
between groups.
Figure 2 shows the standardized between-group differences
(and 95% CI) for the evaluated blood variables. Apart from
the large differences recorded for vitamin C and resistin
concentrations, only NT and reduced glutathione variations
were affected by the antioxidant treatment.
According to the results of the robust linear regression,
changes in resistin serum levels were inversely related to
changes in vitamin C plasma levels both in the experimental
and control groups. On the whole sample, a one-unit increase
in before–after change of vitamin C corresponded to a
statistically signiﬁcant decrease (beta ¼  0.10; 95% CI  0.13,
 0.08; p , 0.001) in the mean change of resistin. This overall
relationship still holds after adjusting by group (beta¼ 0.08;
95% CI  0.13,  0.03; p ¼ 0.003).
Figure 3 reports the observed and predicted values, with
95% conﬁdence bands, estimated for both experimental and
control groups.
Adverse Events
Two participants in the experimental group complained of
gastric discomfort after vitamin C supplementation.
Figure 1. Flow Diagram of the Trial
doi:10.1371/journal.pctr.0020017.g001
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Interpretation
The results of this trial clearly indicated that in healthy
individuals resistin serum levels were signiﬁcantly reduced by
a short period of supplementation with vitamin C. This
treatment was also associated with other changes in oxida-
tion-related variables (reduction of NT levels and incremen-
tal increase of reduced glutathione).
To date, there has been considerable controversy sur-
rounding the physiological relevance of resistin: the associ-
ations with insulin resistance and obesity, reported in mice,
have not been conclusively demonstrated in humans [7–13].
Growing evidence has suggested that this protein, highly
expressed in monocytes and macrophages in humans, might
have an involvement in the inﬂammation process, either
being induced by increased cytokine levels, or directly
stimulating the production of pro-inﬂammatory cytokines,
thus leading to inﬂammation ampliﬁcation [4,12–22]. Recent
studies found that resistin activated human endothelial cells
in vitro, inducing the expression of endothelin 1, adhesion
molecules, and chemokines [16,30], and stimulated smooth
muscle cell proliferation [31]. Endothelial dysfunction and/or
pro-inﬂammatory effects could represent, thus, the link
between higher resistin serum levels and increased preva-
lence of cardiovascular diseases in humans. This latter
association was demonstrated by some studies [20,32,33] and
supported by the ﬁnding of elevated resistin secretion from
macrophages inﬁltrating atherosclerotic arterial walls [34].
It was recently demonstrated that resistin impairs endo-
thelium-dependent vasorelaxation in porcine coronary ar-
teries, by reducing NO bio-availability [35]. Possible
participation of resistin in oxidative processes has been
sporadically suggested [22–26], and an impact of oxidative
stress on the regulation of murine adipokine gene expression
was proposed [36]. The possibility that antioxidants might act
on resistin expression and levels has been suggested by a few
studies on animals: retinoic acid inhibits the expression of
resistin in mice [24], and the antioxidant seleno-methionine,
which increases the activity of glutathione peroxidase in
endothelial cells, completely blocks vasomotor dysfunction
induced by resistin in porcine arteries [35]. In humans, a
small study testing the effect of a chronic treatment with
retinoid therapy on patients with psoriasis showed normal-
ization of the increased resistin serum levels, together with a
reduction in insulin sensitivity, without any changes in
circulating adiponectin or tumor necrosis factor concen-
trations [25].
Our data clearly show that the antioxidant supplementa-
tion signiﬁcantly reduced resistin serum levels, but changed
neither metabolic parameters nor hs-CRP levels (Table 2), the
latter being, however, already very low at baseline. In the
control group, unexpectedly, we observed a slight, statistically
signiﬁcant reduction in vitamin C plasma levels and a small
.......................................................................................................................................................................................
Table 1. Clinical and Laboratory Characteristics of the Participants Studied
Variables Variable Specifications Experimental Group (n ¼ 40) Control Group (n ¼ 40)
Age (years) 34.4 6 8.1 34.0 6 8.0
Age groups (%) 20–30 y 45.0 47.5
31–40 y 25.0 22.5
41–50 y 30.0 30.0
Males (%) 30.0 32.5
Non-smoking (%) 87.5 87.5
Education level (%) University 62.5 55.0
Secondary school 30.0 37.5
Physical activity (%) Light 62.5 65.0
Moderate 32.5 27.5
Heavy 5.0 7.5
Alcohol (g/d) 2.5 6 5.7 2.0 6 5.5
Height (m) 1.68 6 0.1 1.69 6 0.1
Weight (kg)
a 61.5 6 12.7 63.0 6 12.2
Waist circumference (cm) 73.9 6 12.0 75.6 6 10.9
Waist-to-hip ratio 0.79 6 0.09 0.80 6 10.08
Body mass index (kg/m
2) 21.7 6 3.0 22.1 6 2.4
Systolic pressure (mm Hg) 118.0 6 11.6 119.4 6 14.0
Diastolic pressure (mm Hg) 74.9 6 7.4 74.5 6 7.7
Fasting glucose (mmol/l) 4.7 6 0.5 4.6 6 0.4
Total cholesterol (mmol/l) 4.9 6 0.8 4.9 6 0.9
HDL cholesterol (mmol/l) 1.4 6 0.3 1.5 6 0.3
Triglycerides (mmol/l)
b 0.8 (0.6) 0.8 (0.3)
Fasting insulin (pmol/l)
b 80.4 (56.4) 81.9 (58.8)
CRP (mg/l)
b 0.6 (1.0) 0.6 (0.8)
Resistin (ng/ml) 4.3 6 1.5 4.2 6 1.0
Vitamin C (mg/l) 9.4 6 2.9 9.3 6 2.3
Vitamin A (mg/l) 0.45 6 0.13 0.47 6 0.12
Vitamin E (mg/l) 12.0 6 3.2 12.9 6 3.7
Reduced glutathione (lmol/l) 1,428.6 6 271.7 1,492.9 6 352.8
Oxidized glutathione (lmol/l) 333.0 6 124.5 358.2 6 123.8
NT (nmol/ml) 16.7 6 5.3 15.0 6 4.5
aRanges respectively 41–98 kg and 43–93 kg in the experimental and control groups.
bMedian 6 interquartile range for non-normally distributed values.
doi:10.1371/journal.pctr.0020017.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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was independent from changes in other metabolic/inﬂamma-
tory parameters, in line with the absence of correlations
between tumor necrosis factor and resistin changes observed
in males with psoriasis who received retinoid treatment [25].
This suggested a speciﬁc dire c te f f e c to fa n t i o x i d a n t
substances on resistin expression from monocytes/macro-
phages. Accordingly, the reduction in resistin levels was
maintained 3 mo after retinoid treatment in males with
psoriasis, unlike the transient effect found by the authors on
insulin sensitivity [25].
It has been suggested that resistin inhibits endothelial
nitric oxide synthase activation in vitro and increases
superoxide radical production in porcine coronary arteries
[35] and human endothelial cells [26], thus reducing NO bio-
availability. Imbalance in the production and regulation of
oxygen radicals and the subsequent oxidative inactivation of
NO leads to oxidative stress and might contribute to vascular
disease [36].
The reaction of NO with superoxide anion radicals (O2
  )
yields peroxynitrite (ONOO
 ), which can oxidize many bio-
molecules. NT, generated from the oxidation of tyrosine, has
been considered as a measure of ONOO
 oxidative injury, and
elevated plasma levels have been reported in conditions
associatedwithoxidativestress,suchasdiabetes[37–39].Inthe
experimental group, NT levels weresigniﬁcantly reduced after
the supplementation, while a very slight increase was evident
in the control group. These changes might be due to the direct
protective antioxidant effect of vitamin C.Ascorbic acid could
stimulate reduced glutathione synthesis, and, thus, might be
responsible for the statistically signiﬁcant incremental in-
crease in its levels found in the experimental group [40].
Our study is to our knowledge the ﬁrst human randomized
trial carried out on a very homogeneous sample of healthy
volunteers that has demonstrated that short-term supple-
mentation with an antioxidant vitamin might signiﬁcantly
reduce resistin serum levels, independent of changes in
inﬂammatory and metabolic variables. This ﬁnding, together
with in vitro results [26,35], indicates that oxidative stress may
be one of the major mechanisms by which resistin acts and is
Figure 2. Means and 95% CIs of Between-Group Differences of Changes
(in Standardized Units) for the Blood Variables Compared (Experimental
Minus Control Group)
For this analysis, all the variables were standardized (mean/overall standard
deviation).
doi:10.1371/journal.pctr.0020017.g002
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Table 2. Concentrations of Different Blood Variables before and after Vitamin C Supplementation by Group: Absolute Difference
(End-of-Study Minus Baseline Values) with 95% CIs
Blood Variable Experimental Group (n ¼ 40) Control Group (n ¼ 38) p-Value
a
Before After Difference 95% CI Before After Difference 95% CI
Vitamin C (mg/l) 9.4 6 2.9 19.0 6 5.2 9.55 7.91; 11.2 9.3 6 2.3 8.0 6 3.4  1.28  2.32;  0.25 ,0.001
Resistin (ng/ml) 4.3 6 1.5 2.9 6 0.8  1.45  1.87;  1.03 4.2 6 1.0 4.3 6 0.9 0.15  0.07; 0.37 ,0.001
Fasting glucose
(mmol/l)
4.7 6 0.5 4.7 6 0.5  0.04  0.15; 0.08 4.6 6 0.4 4.6 6 0.3 0.01  0.06; 0.09 0.46
Total cholesterol
(mmol/l)
4.9 6 0.8 4.9 6 0.9  0.03  0.20; 0.15 4.9 6 0.9 4.9 6 0.8  0.02  0.28; 0.23 0.97
HDL cholesterol
(mmol/l)
1.4 6 0.3 1.4 6 0.3  0.005  0.06; 0.05 1.5 6 0.3 1.4 6 0.3  0.02  0.09; 0.05 0.73
Log triglycerides
(mmol/l)
b
 0.1 6 0.6  0.1 6 0.4 0.01  0.12; 0.14  0.2 6 0.6  0.2 6 0.3 0.02  0.06; 0.10 0.91
c
Log fasting insulin
(pmol/l)
b
4.5 6 0.6 4.4 6 0.3  0.07  0.25; 0.11 4.4 6 0.5 4.4 6 0.4 0.0004  0.19; 0.19 0.59
c
Log CRP (mg/l)
b  0.6 6 1.0  0.6 6 1.1 0.04  0.33; 0.42  0.4 6 0.9 0.01 6 0.9 0.42 0.06; 0.77 0.15
c
Vitamin A (mg/l) 0.45 6 0.13 0.48 6 0.15 0.03  0.03; 0.09 0.48 6 0.12 0.46 6 0.16  0.01  0.07; 0.04 0.29
Vitamin E (mg/l) 12.0 6 3.2 12.7 6 3.5 0.68  0.92; 2.28 12.9 6 3.7 13.4 6 3.9 0.48  0.74; 1.71 0.85
Reduced
glutathione
(lmol/l)
1,428.6 6 271.7 1,789.0 6 415.1 360.4 245.3; 475.5 1,493.6 6 362.0 1,625.8 6 371.1 129.6 24.4; 234.8 0.004
Oxidized glutathione
(lmol/l)
333.0 6 124.5 376.5 6 154.7 43.5  15.2; 102.2 364.5 6 123.8 370.0 6 115.7 4.59  51.2; 60.4 0.34
Reduced/oxidized
glutathione
5.0 6 2.3 6.1 6 4.3 1.12  0.26; 2.49 4.5 6 1.6 5.0 6 2.7 0.45  0.49; 1.39 0.42
NT (nmol/ml) 16.7 6 5.3 14.4 6 4.0  2.22  3.85;  0.60 15.0 6 4.5 15.2 6 5.7 0.17  1.68; 2.02 0.05
ap-Values were obtained by comparing differences in the concentrations of the blood variables between the two groups using Student’s t-test, unless otherwise noted.
bLog-transformed values for non-normally distributed values.
cp-Values were obtained by comparing differences in the log concentrations of the blood variables between the two groups using Student’s t-test.
doi:10.1371/journal.pctr.0020017.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Antioxidant Treatment and Resistin Levelsregulated. It could be hypothesized that the raised resistin
values occasionally found to be associated with type 2
diabetes or obesity and, more consistently, with endothelial
dysfunction and inﬂammation, rather than being linked to
insulin resistance, might be associated with increased
oxidative stress, common to all these conditions [41,42].
Limitations
Oxidative stress is not an easily deﬁnable condition, and none
of the indices used for its evaluation could be deﬁned as the
most appropriate criterion in universal terms [43]. Problems
of low protocol adherence were not documented. Contam-
ination between the two groups seems unlikely due to the
short-term and simple regimen of the intervention.
The open nature of the study and the lack of a placebo
might have affected participants’ behavior during the trial.
However, it is quite unlikely that this could represent a source
of measurement bias, since all the end points (e.g., the
relationship between vitamin C and resistin levels) were
blood measurements, blindly assessed by the same laboratory.
It is unlikely that dietary patterns would have changed
substantially from June–July 2005 to September–November
2005; moreover, all the participants were advised to continue
their habitual diet. As participants were randomly allocated
in the two groups and were similar for many environmental
characteristics (smoking, alcohol and nutrient intake, educa-
tion level, and physical activity), there is no reason why only
one group should have changed dietary habits. Vitamin C
levels slightly decreased in the control group, and a seasonal
effect might be the most probable cause (higher fruit/
vegetable intake is expected during the summer). In the
experimental group, this change might not be appreciable,
owing to the ascorbic acid supplementation received. The
slight reduction in vitamin C plasma levels of the control
individuals corresponded to a small increase in their serum
resistin values. This unexpected ﬁnding is not only consistent
with but it also further strengthens the results found in the
experimental group.
The loss of two volunteers in the control group, because
they moved away, is unlikely to have inﬂuenced the main
results of the study. An intention-to-treat analysis, assuming
for these two control individuals the same average resistin
reduction of the experimental group, conﬁrmed the results.
Until further studies conﬁrm these results in other cohorts
(patients with diabetes, obesity, etc.) and the potential
beneﬁts of antioxidant treatment are demonstrated, no
clinical consideration could be extrapolated from our data.
Generalizability
This explicative trial was performed in healthy volunteers,
and it may be reasonable to generalize its results to healthy
groups. Further studies are needed to test these relationships
in individuals with health problems or who are taking
medication.
Overall Evidence
Existing evidence on resistin participation in oxidative
processes is scarce and heterogeneous; most studies were
performed in vitro or in animals [23,24,26]. In humans, a
small study on patients with psoriasis showed normalization
of the increased resistin serum levels after treatment with
retinoid therapy [25]. This is to our knowledge the ﬁrst trial
in humans designed to assess the impact in vivo of
antioxidant treatment on resistin serum levels. Its main result
is that vitamin C signiﬁcantly reduced resistin, without
Figure 3. Before–After Change in Resistin versus Before–After Change of Vitamin C
Overall plot of observed (circles) and predicted values (solid line) of variation of resistin (with 95% confidence bands; dotted lines) according to the before–after
change of vitamin C concentrations (end-of-study minus baseline values). Solid black circles represent the experimental group; open grey circles represent the
control group.
doi:10.1371/journal.pctr.0020017.g003
www.plosclinicaltrials.org May | 2007 | e17 0007
Antioxidant Treatment and Resistin Levels........................................................................................
changing other metabolic/inﬂammatory parameters. This
suggests a speciﬁc direct effect of antioxidant substances on
resistin expression from monocytes/macrophages.
Conclusion
The exact biological role of resistin in humans remains so far
equivocal. These results add some data to currently available
knowledge by demonstrating an inverse relationship between
blood levels of resistin and vitamin C. Future investigations
on resistin participation in oxidative processes are warranted
to further clarify the intriguing, but not well-deﬁned role of
this protein in chronic degenerative diseases.
SUPPORTING INFORMATION
CONSORT Checklist
Found at doi:10.1371/journal.pctr.0020017.sd001 (41 KB DOC).
Trial Protocol
Found at doi:10.1371/journal.pctr.0020017.sd002 (47 KB DOC).
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